JP Morgan Chase
JUNO

JP Morgan Chase’s Juno Therapeutics, Inc. JUNO Stock Holding History

JP Morgan Chase’s Portfolio JUNO Stock Details JUNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-70,286
Closed -$3.21M – 5792
2017
Q4 		$3.21M Sell
70,286
-14,888
-17% -$743K ﹤0.01% 3016
2017
Q3 		$3.79M Sell
85,174
-27,950
-25% -$953K ﹤0.01% 2765
2017
Q2 		$3.38M Buy
113,124
+50,378
+80% +$1.24M ﹤0.01% 2735
2017
Q1 		$1.39M Buy
62,746
+60,001
+2,186% +$1.29M ﹤0.01% 3242
2016
Q4 		$51K Sell
2,745
-2,447
-47% -$59.9K ﹤0.01% 4547
2016
Q3 		$156K Buy
5,192
+418
+9% +$13K ﹤0.01% 3761
2016
Q2 		$184K Sell
4,774
-670
-12% -$27.8K ﹤0.01% 3745
2016
Q1 		$207K Sell
5,444
-47,086
-90% -$1.64M ﹤0.01% 3610
2015
Q4 		$2.31M Sell
52,530
-100,865
-66% -$5M ﹤0.01% 2682
2015
Q3 		$6.24M Sell
153,395
-301,651
-66% -$13.2M ﹤0.01% 2083
2015
Q2 		$24.3M Buy
455,046
+396,163
+673% +$21M 0.01% 1284
2015
Q1 		$3.57M Buy
58,883
+14,921
+34% +$724K ﹤0.01% 2561
2014
Q4 		$2.3M Buy
+43,962
New +$1.97M ﹤0.01% 2883

Other funds holding JUNO

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM

JP Morgan Chase's JUNO Position: Q1 2018 in Review

JP Morgan Chase sold out of Juno Therapeutics, Inc. (JUNO) in Q1 2018, closing a stake of 70,286 shares — an estimated $3.21M sold.

JP Morgan Chase first reported a position in JUNO in Q4 2014 and held it in 13 quarters. The position peaked at $24.3M in Q2 2015. 2 funds tracked by Wall St. Rank hold JUNO as of Q1 2018.

  • JP Morgan Chase reported no remaining Juno Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
  • JP Morgan Chase sold 70,286 Juno Therapeutics, Inc. shares in Q1 2018, an estimated $3.21M.
  • JP Morgan Chase first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 13 quarters.
  • JP Morgan Chase's Juno Therapeutics, Inc. position peaked at $24.3M in Q2 2015.
  • 2 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q1 2018.

Based on JP Morgan Chase's 13F filing for Q1 2018, filed 10 May 2018.